Showing results (1-10 of 11) with videos related to
Sort By:
Pageof 2
Journal of Occupational and Environmental Hygiene|April 24, 2019
Effect of hollow bit local exhaust ventilation on respirable quartz dust concentrations during concrete drillingDavid Rempel, Alan Barr, Michael R CooperPublic Health Reports (Washington, D.C. : 1974)|July 22, 2009
Engineering control technologies to reduce occupational silica exposures in masonry cutting and tuckpointingJohn D Meeker, Michael R Cooper, Daniel Lefkowitz, et al.Journal of Occupational and Environmental Hygiene|November 20, 2018
Exposure to airborne nano-titanium dioxide during airless spray painting and sandingGavin H West, Michael R Cooper, Leonard G Burrelli, et al.Annals of Work Exposures and Health|June 9, 2017
The Effects of Bit Wear on Respirable Silica Dust, Noise and Productivity: A Hammer Drill Bench StudyPaul Carty, Michael R Cooper, Alan Barr, et al.Applied Ergonomics|November 30, 2018
Pneumatic rock drill vs. electric rotary hammer drill: Productivity, vibration, dust, and noise when drilling into concreteDavid Rempel, Andrea Antonucci, Alan Barr, et al.American Journal of Industrial Medicine|June 5, 2024
Characterizing applications, exposure risks, and hazard communication for engineered nanomaterials in constructionBruce E Lippy, Sara B Brooks, Michael R Cooper, et al.Journal of Occupational and Environmental Hygiene|May 14, 2021
Occupational exposure risk during spraying of biocidal paint containing silver nanoparticlesGavin H West, Fatima I Castaneda, Leonard G Burrelli, et al.Journal of Occupational and Environmental Hygiene|April 14, 2017
Inhalation exposure during spray application and subsequent sanding of a wood sealant containing zinc oxide nanoparticlesMichael R Cooper, Gavin H West, Leonard G Burrelli, et al.Brain Sciences|March 28, 2025
The Relationship Between Concussion and Combat History and Mental Health and Suicide Ideation Among United States Military Veterans-A Pilot StudyScott L Bruce, Michael R Cooper, Carly Farmer, et al.Blood|August 12, 2006
Phase 1 clinical results with tandutinib (MLN518), a novel FLT3 antagonist, in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome: safety, pharmacokinetics, and pharmacodynamicsDaniel J DeAngelo, Richard M Stone, Mark L Heaney, et al.Pageof 2